Check the time stamp on this data. Updated AI-Generated Signals for Viking Therapeutics Inc. (VKTX) available here: VKTX.
Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.
H.C. Wainwright has recently reiterated Viking Therapeutics Inc (VKTX) stock to Buy rating, as announced on November 4, 2024, according to Finviz. Earlier, on September 11, 2024, JP Morgan had ...
On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...
Viking Therapeutics(NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of ...
6don MSN
A new stronger Ozempic is coming. Here’s what to knowNovo Nordisk (NVO) teased some new details about a potential Ozempic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback